Copyright © 2003 by the European Society of Cardiology.
ACC/ESC Expert consensus document
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy
A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Writing Committee Members,
ACCF Task Force on Clinical Expert Consensus Documents Members,
ESC Committee for Practice Guidelines Members*,
| The first 150 words of the full text of this article appear below. |
Table of contents
- Preamble
- Introduction
- Organization of committee and evidence review
- Purpose of this Expert Consensus Document
- General considerations and perspectives
- Nomenclature, definitions, and clinical diagnosis
- Obstruction to LV Outflow
- Genetics and molecular diagnosis
- General considerations for natural history, and clinical course
- Symptoms and pharmacological managementstrategies
- Beta-adrenergic blocking agents
- Verapamil
- Disopyramide
- Drugs in end-stage phase
- Asymptomatic patients
- Infective endocarditis prophylaxis
- Pregnancy
- Treatment options for drug-refractory patients
- Additional approaches to relieve outflowobstruction and symptoms
- Dual-chamber pacing
- Percutaneous alcohol septal ablation
- Sudden Cardiac Death
- Risk stratification
- Prevention
- Athlete recommendations
- Atrial Fibrillation
- References
- Introduction
Preamble
This document has been developed as a Clinical Expert Consensus Document (CECD), combining the resources of the American College of Cardiology Foundation (ACCF) and the European Society of Cardiology (ESC). It is intended to provide a perspective on the current state of management of patients with hypertrophic cardiomyopathy. Clinical Expert Consensus Documents are intended to inform practitioners, payers, and other interested parties of
Introduction
Organization of committee and evidence review
Purpose of this Expert Consensus Document
General considerations and perspectives
Nomenclature, definitions, and clinical diagnosis
Obstruction to LV Outflow
Genetics and molecular diagnosis
General considerations for natural history, and clinical course
Symptoms and pharmacological management strategies
Beta-adrenergic blocking agents
Verapamil
Disopyramide
Drugs in end-stage phase
Asymptomatic patients
Infective endocarditis prophylaxis
Pregnancy
Treatment options for drug-refractory patients
Additional approaches to relieve outflow obstruction and symptoms
Dual-chamber pacing
Percutaneous alcohol septal ablation
Sudden Cardiac Death
Risk stratification
Prevention
Athlete recommendations
Atrial Fibrillation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Michels, O. I.I. Soliman, J. Phefferkorn, Y. M. Hoedemaekers, M. J. Kofflard, D. Dooijes, D. Majoor-Krakauer, and F. J. Ten Cate Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers Eur. Heart J., November 1, 2009; 30(21): 2593 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Gimeno, M. Tome-Esteban, C. Lofiego, J. Hurtado, A. Pantazis, B. Mist, P. Lambiase, W. J. McKenna, and P. M. Elliott Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy Eur. Heart J., November 1, 2009; 30(21): 2599 - 2605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Leonardi, C. Raineri, G. M. De Ferrari, S. Ghio, L. Scelsi, M. Pasotti, M. Tagliani, A. Valentini, R. Dore, A. Raisaro, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy Eur. Heart J., August 2, 2009; 30(16): 2003 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O'Mahony and P. Elliott The quest for perfection: the contribution of the electrocardiogram to the prevention of sudden death in hypertrophic cardiomyopathy Europace, May 1, 2009; 11(5): 548 - 549. [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. ElBardissi Letter by ElBardissi Regarding Article, "Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy" Circulation, February 3, 2009; 119(4): e187 - e187. [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Hess, W. McKenna, and H.-P. Schultheiss CHAPTER 18 Myocardial Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Eckardt, G&#x.;n. Breithardt, and S. Hohnloser CHAPTER 30 Ventricular Tachycardia and Sudden Cardiac Death ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Malek, L. Chojnowska, M. Klopotowski, R. Maczynska, M. Demkow, A. Witkowski, B. Kusmierczyk, E. Piotrowicz, M. Konka, M. Dabrowski, et al. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation Eur J Heart Fail, November 1, 2008; 10(11): 1123 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Shah, M T T Esteban, R Thaman, R Sharma, B Mist, A Pantazis, D Ward, S K Kohli, S P Page, C Demetrescu, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy Heart, October 1, 2008; 94(10): 1288 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J P Kaski, M T Tome-Esteban, S Mead-Regan, A Pantazis, J Marek, J E Deanfield, W J McKenna, and P M Elliott B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy Heart, October 1, 2008; 94(10): 1307 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Elliott and P Spirito Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice Heart, October 1, 2008; 94(10): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sen-Chowdhry and W. J. McKenna Non-invasive risk stratification in hypertrophic cardiomyopathy: don't throw out the baby with the bathwater Eur. Heart J., July 1, 2008; 29(13): 1600 - 1602. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sotgia, R. Sciagra, I. Olivotto, G. Casolo, L. Rega, I. Betti, A. Pupi, P. G. Camici, and F. Cecchi Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy J. Nucl. Med., July 1, 2008; 49(7): 1090 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dandona and R. Roberts Identification of Myofilament Mutations: Its Role in the Diagnosis and Management of Hypertrophic Cardiomyopathy Mayo Clin. Proc., June 1, 2008; 83(6): 626 - 627. [Full Text] [PDF]
|
|
|
|
|
|
P. Elliott, B. Andersson, E. Arbustini, Z. Bilinska, F. Cecchi, P. Charron, O. Dubourg, U. Kuhl, B. Maisch, W. J. McKenna, et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases Eur. Heart J., January 2, 2008; 29(2): 270 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. ElBardissi, J. A. Dearani, R. A. Nishimura, S. R. Ommen, J. M. Stulak, and H. V. Schaff Septal Myectomy After Previous Septal Artery Ablation in Hypertrophic Cardiomyopathy Mayo Clin. Proc., December 1, 2007; 82(12): 1516 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Monserrat, M. Hermida-Prieto, X. Fernandez, I. Rodriguez, C. Dumont, L. Cazon, M. G. Cuesta, C. Gonzalez-Juanatey, J. Peteiro, N. Alvarez, et al. Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects Eur. Heart J., August 2, 2007; 28(16): 1953 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Spirito and C. Autore Apical hypertrophic cardiomyopathy or left ventricular non-compaction? A difficult differential diagnosis Eur. Heart J., August 2, 2007; 28(16): 1923 - 1924. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Fifer Most Fully Informed Patients Choose Septal Ablation Over Septal Myectomy Circulation, July 10, 2007; 116(2): 207 - 216. [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Heldman, K. C. Wu, T. P. Abraham, and D. E. Cameron Myectomy or Alcohol Septal Ablation: Surgery and Percutaneous Intervention Go Another Round J. Am. Coll. Cardiol., January 23, 2007; 49(3): 358 - 360. [Full Text] [PDF]
|
|
|
|
|
|
K Debl, B Djavidani, S Buchner, C Lipke, W Nitz, S Feuerbach, G Riegger, and A Luchner Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis Heart, October 1, 2006; 92(10): 1447 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Damgaard and O. Faergeman Genotypes or phenotypes in cardiovascular diagnosis? Eur. Heart J., September 2, 2006; 27(18): 2150 - 2151. [Full Text] [PDF]
|
|
|
|
|
|
P. Charron Clinical genetics in cardiology. Heart, August 1, 2006; 92(8): 1172 - 1176. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Dumont, L. Monserrat, R. Soler, E. Rodriguez, X. Fernandez, J. Peteiro, A. Bouzas, B. Bouzas, and A. Castro-Beiras Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance Eur. Heart J., July 2, 2006; 27(14): 1725 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D'Andrea, P. Caso, S. Severino, S. Cuomo, G. Capozzi, P. Calabro, G. Cice, L. Ascione, M. Scherillo, and R. Calabro Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy Eur. Heart J., June 1, 2006; 27(11): 1311 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A D'Andrea, P Caso, S Cuomo, G Salerno, R Scarafile, C Mita, G De Corato, B Sarubbi, M Scherillo, R Calabro, et al. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes * Commentary. Br. J. Sports Med., March 1, 2006; 40(3): 244 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Anastasakis, C Kotsiopoulou, A Rigopoulos, A Theopistou, N Protonotarios, D Panagiotakos, N Mammalis, and C Stefanadis Similarities in the profile of cardiopulmonary exercise testing between patients with hypertrophic cardiomyopathy and strength athletes Heart, November 1, 2005; 91(11): 1477 - 1478. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Forissier, P. Charron, S. T. du Montcel, A. Hagege, R. Isnard, L. Carrier, P. Richard, M. Desnos, J. B. Bouhour, K. Schwartz, et al. Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy Eur. Heart J., September 2, 2005; 26(18): 1882 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts and U. Sigwart Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy Circulation, July 12, 2005; 112(2): 293 - 296. [Full Text] [PDF]
|
|
|
|
|
|
A Miliou, A Anastasakis, L G D'Cruz, A Theopistou, A Rigopoulos, I Rizos, S Stamatelopoulos, P Toutouzas, and C Stefanadis Low prevalence of cardiac troponin T mutations in a Greek hypertrophic cardiomyopathy cohort Heart, July 1, 2005; 91(7): 966 - 967. [Full Text] [PDF]
|
|
|
|
|
|
O-A Breithardt, G Beer, B Stolle, F Lieder, A Franke, T Lawrenz, P Hanrath, and H Kuhn Mid systolic septal deceleration in hypertrophic cardiomyopathy: clinical value and insights into the pathophysiology of outflow tract obstruction by tissue Doppler echocardiography Heart, March 1, 2005; 91(3): 379 - 380. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Faber, H. Seggewiss, D. Welge, D. Fassbender, H. K. Schmidt, U. Gleichmann, and D. Horstkotte Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience Eur J Echocardiogr, October 1, 2004; 5(5): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Nishimura and D. R. Holmes Jr. Hypertrophic Obstructive Cardiomyopathy N. Engl. J. Med., March 25, 2004; 350(13): 1320 - 1327. [Full Text] [PDF]
|
|